Abstract
Introduction: Because of bilateral involvement in many cases with diabetic macular edema, Intravitreal bevacizumab injection perform in both eyes. There are some reports of therapeutic effects in the fellow eye after monocular injection of anti-vascular endothelial growth factors. In this study we describe a case of bilateral improvement of diabetic macular edema following unilateral intravitreal bevacizumab injection. Case Presentation: We report a patient with bilateral non-proliferative diabetic retinopathy and diabetic macular edema. Central macular thickness was 398µ in the right eye and 337µ in the left eye. Two months after intravitreal injection of 1.25mg bevacizumab in the right eye, significant improvement of diabetic macular edema was happened in both eyes including the left eye without intravitral injection. Central macular thickness was 245µ in the right eye and 250µ in the left eye. Conclusion: Unilateral injection of intravitreal bevacizumab may have therapeutic effects in the fellow untreated eye. Therefore; unilateral injection in bilateral cases may reduce the costs and complications of bilateral injection.
Highlights
Because of bilateral involvement in many cases with diabetic macular edema, intravitreal bevacizumab injection perform in both eyes
The current study describes an interesting case of significant improvement of diabetic macular edema (DME) in the contralateral eye after the monocular intravitreal injection of bevacizumab
Another study by Velez-Montoya et al showed that unilateral bevacizumab injection in 23 patients with bilateral DME had no effect on the fellow eye.[7]
Summary
Bevacizumab is a recombinant humanized monoclonal antibody directed against human vascular endothelial growth factor (VEGF).[1]. The current study describes an interesting case of significant improvement of DME in the contralateral eye after the monocular intravitreal injection of bevacizumab. Intravitreal injection of 1.25 mg/0.05 mL bevacizumab was performed in the right eye. Two months later the patient presented for examination, and OCT was done. Significant improvement of DME had occurred in both eyes, including the left eye that had not received intravitreal injection. Central macular thickness was 245 μ in the right eye and 250 μ in the left eye (Figures 2A & B).
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
